复发难治性急性白血病多药耐药逆转的临床研究  

Clinical study on reversal of multidrug resistance in relapsed or refractory acute leukemias by cyclosporine A and interferon

作　　者：王武明 山顺林 

机构地区：[1]解放军八二医院,江苏淮安223001

出　　处：《现代肿瘤医学》2011年第3期545-547,共3页Journal of Modern Oncology

摘　　要：目的:探讨环孢素A(CsA)联合α-干扰素(IFN-α)逆转复发难治性急性白血病的临床疗效。方法:彩用免疫组织化学标记链亲和法检测初诊急性白血病的P-糖蛋白表达。将P-糖蛋白阳性者随机分为两组,比较CsA联合IFN-α加化疗组与单用化疗组的疗效。结果:P-糖蛋白的阳性表达率在非难治性急性白血病为10.9%,在难治性急性白血病为66.7%(P<0.01)。CsA联合IFN-α对逆转难治性急性白血病的多药耐药有一定作用,加逆转剂组缓解率(CR+PR)及完全缓解期高于不加逆剂组(P<0.05)。结论:CsA联合IFN-α逆转难治性急性白血病安全有效。Objective：To explore the clinical implication of reversal of multidrug resistance（MDR）by cyclosporine A（CsA） and interferon-α（IFN-α）.Methods： The expression of P-170 was assaied by means of immunocytochemistry,45 cases who were P-170 positive were randomly divided into groups： trial group（chemotherapy plus CSA and IFN-α）and control group（chemotherapy alone）.Results： The incidence of P-170 expression（66.7%）was higher in relapsed of refractory acute leukemias,effective rates were 78.9% and 42.9% respression（P0.05）.Conclusion： CsA and IFN-a were safe and effective for reversal of MDR in relapsed or retractory acute leukemia.

关 键 词：药物耐受性 急性白血病 药物疗法 环胞素A 干扰素 

分 类 号：R733.71[医药卫生—肿瘤]